Preclinical study reveals transcriptional-translational conflict in ARID1A-deficient bladder tumors, highlighting therapeutic potential for protein synthesis inhibitors.
In a recent publication in Cancer Cell , Jana et al. uncover a phenomenon they call ‘transcriptional-translational conflict’ (TTC) where deletion of the ARID1A tumor suppressor elevated proliferation-associated transcripts, but up to 70% of upregulated mRNAs displayed no corresponding change in protein levels. 1 The clinical implication of these findings is that patients with ARID1A-deficient bladder tumors may be susceptible to treatment with pharmacological inhibitors of protein synthesis.
No takes yet. Share an insight, caveat, or question.
Mudryj et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: